+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Compound selection for in vitro modeling of developmental neurotoxicity



Compound selection for in vitro modeling of developmental neurotoxicity



Frontiers in Bioscience 17: 2442-2460



Development of in vitro systems, such as those based on embryonic stem cell differentiation, depends on the selection of adequate test and training compounds. We recommend the use of two classes of positive controls, the "gold standard compounds" for which developmental neurotoxicity (DNT) has been proven in man, and the "pathway compounds" that are known to disrupt signalling pathways and key processes relevant for neuronal differentiation. We introduce the concept of toxicity endophenotypes (TEP) as changes in neuronal connectivity resulting from exposure to developmental toxicants. Thus, TEPs provide the scientific rationale for modeling DNT with simple in vitro models of key neurodevelopmental events. In this context, we discuss scientific and technical aspects of the test compound selection process. We suggest to include compounds with unspecific toxicity, besides negative control compounds, and we recommend tandem approaches to determine relative toxicities instead of absolute measures. Finally, we discuss how to avoid pitfalls by distinguishing between unspecific forms of cytotoxicity and specific developmental neurotoxicity. A compilation of compound lists corresponding to the above-discussed principles supplement this review.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052269233

Download citation: RISBibTeXText

PMID: 22652791

DOI: 10.2741/4064


Related references

Modeling the developmental neurotoxicity of chlorpyrifos in vitro: macromolecule synthesis in PC12 cells. Toxicology and Applied Pharmacology 156(1): 78-80, 1999

Modeling the developmental neurotoxicity of nicotine in vitro: cell acquisition, growth and viability in PC12 cells. Brain Research. Developmental Brain Research 154(2): 239-246, 2005

Dose-response modeling for developmental neurotoxicity data. Environmental & Ecological Statistics 7(2): 191-203, June, 2000

Workshop on the qualitative and quantitative comparability of human and animal developmental neurotoxicity, Work Group IV report: triggers for developmental neurotoxicity testing. Neurotoxicology and Teratology 12(3): 281-284, 1990

Developmental neurotoxicity testing: scientific approaches towards the next generation to protect the developing nervous system of children. An overview of the Developmental Neurotoxicity Symposium in 2011. Congenital Anomalies 52(3): 119-121, 2013

Modeling anesthetic developmental neurotoxicity using human stem cells. Seminars in Cardiothoracic and Vascular Anesthesia 17(4): 276-287, 2014

Workshop on the qualitative and quantitative comparability of human and animal developmental neurotoxicity, Work Group II report: testing methods in developmental neurotoxicity for use in human risk assessment. Neurotoxicology and Teratology 12(3): 269-274, 1990

Workshop on the qualitative and quantitative comparability of human and animal developmental neurotoxicity, Work Group I report: comparability of measures of developmental neurotoxicity in humans and laboratory animals. Neurotoxicology and Teratology 12(3): 261-267, 1990

Workshop on the qualitative and quantitative comparability of human and animal developmental neurotoxicity, Work Group III report: weight of evidence and quantitative evaluation of developmental neurotoxicity data. Neurotoxicology and Teratology 12(3): 275-280, 1990

A new in vitro model for investigating developmental neurotoxicity. Naunyn-Schmiedeberg's Archives of Pharmacology 369(Suppl 1): R138, March, 2004

A new in vitro model for testing developmental neurotoxicity. Toxicology Letters (Shannon) 144(Suppl 1): s133, September, 2003

Pyrazole compound 2-MBAPA as a novel inhibitor of microglial activation and neurotoxicity in vitro and in vivo. Journal of Alzheimer's Disease 27(3): 531-541, 2012

Developmental neurotoxicity of perfluorinated chemicals modeled in vitro. Environmental Health Perspectives 116(6): 716-722, 2008

In vitro and other alternative approaches to developmental neurotoxicity testing (DNT). Environmental Toxicology and Pharmacology 19(3): 735-744, 2005

Reference compounds for alternative test methods to indicate developmental neurotoxicity (DNT) potential of chemicals: example lists and criteria for their selection and use. Altex (): -, 2016